- Home
- IBRX vs PRKS Comparison
IBRX vs PRKS Comparison
Compare IBRX & PRKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IBRX
- PRKS
- Stock Information
- Founded
- IBRX 2014
- PRKS 1959
- Country
- IBRX United States
- PRKS United States
- Employees
- IBRX N/A
- PRKS N/A
- Industry
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- PRKS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- IBRX Health Care
- PRKS Health Care
- Exchange
- IBRX Nasdaq
- PRKS Nasdaq
- Market Cap
- IBRX 2.4B
- PRKS 2.4B
- IPO Year
- IBRX N/A
- PRKS 2013
- Fundamental
- Price
- IBRX $2.06
- PRKS $46.91
- Analyst Decision
- IBRX Strong Buy
- PRKS Buy
- Analyst Count
- IBRX 5
- PRKS 12
- Target Price
- IBRX $11.35
- PRKS $58.50
- AVG Volume (30 Days)
- IBRX 8.8M
- PRKS 717.0K
- Earning Date
- IBRX 05-16-2025
- PRKS 05-12-2025
- Dividend Yield
- IBRX N/A
- PRKS N/A
- EPS Growth
- IBRX N/A
- PRKS 4.41
- EPS
- IBRX N/A
- PRKS 3.79
- Revenue
- IBRX $14,745,000.00
- PRKS $1,725,301,000.00
- Revenue This Year
- IBRX $579.28
- PRKS $2.65
- Revenue Next Year
- IBRX $179.96
- PRKS $2.60
- P/E Ratio
- IBRX N/A
- PRKS $12.00
- Revenue Growth
- IBRX 2270.58
- PRKS N/A
- 52 Week Low
- IBRX $1.83
- PRKS $37.68
- 52 Week High
- IBRX $9.16
- PRKS $60.83
- Technical
- Relative Strength Index (RSI)
- IBRX 36.89
- PRKS 54.65
- Support Level
- IBRX $1.83
- PRKS $44.12
- Resistance Level
- IBRX $2.17
- PRKS $46.55
- Average True Range (ATR)
- IBRX 0.18
- PRKS 1.61
- MACD
- IBRX -0.05
- PRKS 0.43
- Stochastic Oscillator
- IBRX 23.56
- PRKS 84.75
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
About PRKS United Parks & Resorts Inc. Common Stock
United Parks & Resorts Inc is an American theme park and entertainment company. Its core business is the operation of theme parks and entertainment facilities involving sea animals across the country under prominent brands such as SeaWorld, Busch Gardens, Aquatica, Discovery Cove, and Sesame Place. The company generates the majority of its revenue from selling admission tickets for its theme parks.